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Summanr Doxorubicin (5 mg kg- ') wvas administered intravenously to C57 mice bearing subcutaneous
B16FIO melanomas. distributing into the tumour with an area under the concentration-time curve (0-48 h.
AUC) of 8.7 jg h g '. Injection of doxorubicin-.V-(2-hydroxypropyl)methacrylamide (HPMA) copolymer con-
jugate. containing 5 mg of doxorubicin equivalent per kg. mediated an AUC for free doxorubicin (i.e.
doxorubicin released from the conjugate) of 15.2 fig h g-' and for total doxorubicin (i.e. free plus conjugated)
of 149.1 Lg h g-'. An increased dose of doxorubicin-HPMA copolymer conjugate (18 mg of doxorubicin
equivalent per kg) produced AUC values of 40.1 gmg h g-' and 671.7 tLg h g-' for free and total doxorubicin
respectively. Hence administration of doxorubicin-HPMA copolymer conjugate achieved rises of 1.7- to
4.6-fold in tumour AUC (free doxorubicin) and 17.1- to 77.0-fold in tumour AUC (total doxorubicin). HPMA
copolymers bearing fluorescein isothiocvanate accumulated in vascularised stromal regions. particularly in new
growth sites at the tumour periphery. Treatment of mice with doxorubicin-HPMA copolymer conjugate
achieved treated control lifespans up to 320% (three doses of 27 mg of doxorubicin equivalent per kg)
compared with only 13300o using aggressive regimens of free doxorubicin (3 x 5 mg kg-').
The pharmacokinetics of doxorubicin is modified following
covalent conjugation to a copolymer based on V-(2-hydroxv-
propyl)methacrvlamide (HPMA) (Figure 1) (Duncan. 1992).
The doxorubicin-HPMA copolymer conjugate is unable to
diffuse through cellular membranes and consequently dis-
plays a lower volume of distribution and longer plasma
half-life than free doxorubicin (Seymour et al.. 1990). The
poor membrane permeability of the conjugate also prevents
its entry into cardiac tissue. reflected in decreased cardiotox-
icity and permitting administration of increased doses of
doxorubicin as a polymer conjugate (Yeung et al.. 1991).
The doxorubicin-HPMA copolymer conjugate has been
shown to be essentially non-cytotoxic in vitro but to mediate
anti-cancer activity against a range of animal tumour models
in vivo. thought to result from proteolytic activation of the
conjugate within tumour tissue (Duncan et al.. 1992). This
proposed mode of action means that the activity of the drug
conjugate is likely to be influenced by various biological
factors. including biochemical and physiological features of
the tumour.
Cassidy et al. (1989) and Duncan et al. (1992) used high-
performance liquid chromatographic (HPLC) techniques to
show that anthracycline-HPMA copolymer conjugates
achieved high intratumoral levels of drug within established
subcutaneous Walker sarcoma tumours. suggesting an ability
of the drug conjugate to accumulate passively within solid
tumours. However the Walker tumour is known to possess a
relatively permeable vascular system (Butler et al.. 1975). and
it is not clear whether passive tumour tropism and the conse-
quent elevated tumour levels of drug is a significant compo-
nent of the mechanism of action of these anthracycline-
HPMA copolymer conjugates against other solid tumours.
In this study we have examined the activity of doxorubi-
cin-HPMA copolymer conjugate against established s.c.
tumours of murine melanoma B16F10. The pharmacokinetics
and tumour accumulation of the conjugate have been studied
using radiotracing and HPLC-based techniques. and the
intratumoral distribution of fluorescein isothiocyanate-label-
led HPMA copolymer (FITC-HPMA) has been examined by
microscopy to identify sites of permeable vasculature and
macromolecular deposition.
Materials and methods
Reagents
-Amino-2-propanol. methacryloylchloride. dimethylforma-
mide (DMF) and 4-nitrophenol were from Fluka. Buchs.
Switzerland. Glycylphenylalanine and leucylglycine were
from Cambridge Research Biochemicals. Northwich. UK.
Doxorubicin was a kind gift from Farmitalia Carlo Erba.
Milan. Italy. and FITC microscopy reagents and daunomycin
were from Sigma. Poole. UK. HPLC solvents were from
Fisons. Loughborough. UK.
Polymer conjugates
Doxorubicin-HPMA copolymer conjugate (Figure la) was
synthesised as descnrbed in full elsewhere (Rihova et al..
1989): the material used in this study had a weight-average
molecular weight (MW) of 24.000. and polydispersity (ratio
of weight and number average-molecular weight) of 1.3. as
determined by Sepharose 4B 6B gel permeation chromato-
graphy. Doxorubicin content was 7.2% (w w) (2.5 mol%).
To permit radioiodination an HPMA copolymer conjugate of
doxorubicin was synthesised with similar specifications to
contain also methacryloylated tyrosinamide as a comonomer
(.Omol%. component X, Figure la) (Chytry et al.. 1987).
Radiolabelling was performed with ['-51liodide (Amersham
International. UK) using a solid phase oxidising agent
(lodobeads. Pierce Chemicals. Rockford. USA) as described
elsewhere (Seymour et al., 1991). The radiolabelled conjugate
had a specific radioactivity of 80 uCi mg-' conjugate and it
was included at trace levels (1 mCi per mouse) in therapeutic
doses of the unlabelled conjugate to allow monitoring of the
fate of the polymer backbone.
FITC-HPMA was synthesised to permit monitoring of
distribution of the poly-mer b) fluorescence microscopy
(Figure lb). First a polymeric precursor P-GlyGly-ONp [P
represents a poly(HPMA) backbone. GlyGly-ONp is the 4-
nitrophenyl ester of glycyl glycine] was prepared b) radical
precipitation copolymerisation of HPMA with methacryloyl
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Fugwe 1 Structure of HPMA copolymer conjugates used in this
study. a, The HPMA copolymer-doxorubicin conjugates. The
conjugate used at therapeutic concentrations had x = 0, y = 2.5,
z = 97.5. For radiotracing studies, tyrosinamide was incorporated
into the structure to permit iodination and x = 1.0, y = 2.5 and
z = 96.5. b, HPMA copolymer bearing FITC for studies using the
distribution of fluorescence. Full synthetic and characterisation
details are given in the text.
glycyl glycine 4-nitrophenyl ester (MA-GlyGly-ONp) in
acetone as described elsewhere (Rihova et al., 1989). The
polymeric precursor had MW 34,900 and polydispersity 1.44,
and the molar ratio of MA-GlyGly-ONp to HPMA monomer
units was 2 mol%.
Subsequently aminolysis of ONp groups of the polymeric
precursor with a 100-fold molar excess of ethylenediamine
was used to prepare P-GlyGly-HN-(CH2)-NH2 as follows.
Polymeric precursor (0.7 g), dissolved in freshly distilled
DMF (4.0 ml), was added dropwise to a solution of 1.6 ml of
ethylenediamine in 3 ml of DMF at room temperature. The
reaction mixture was stirred for 2 h, the solvent and
ethylenediamine were evaporated under vacuum, 2 ml of
methanol was added and the polymer was isolated by pre-
cipitation into a mixture of acetone-diethyl ether (1:1, v,,v)
and purified by 2-fold reprecipitation of the polymer from
methanol solution into acetone-diethyl ether.
P-GlyGly-HN-(CH2)2-NH, (0.3 g) was then dissolved in
DMF (2.0 ml), FITC (0.156 g in 0.15 ml of DMF) added and
the mixture was stirred for 6h. P-GlyGly-HN-(CH2)2-NH-
FITC was isolated by precipitation into acetone and purified
by double precipitation from methanol into acetone. Final
purification was carried out using a Sephadex G25 column
and then the product, containing 1 mol% FITC, was lyophil-
ised.
Animal model system
Male C57 black 10 mice (6-8 weeks old; Bantin & Kingman,
Hull, UK) were administered s.c. B16FIO melanoma cells
(1Wcells per mouse in 0.1 ml of saline). Because of the
difficulty of precise measurement of tumour depth, tumour
sizes were represented as the product of two orthogonal
diameters, including the longest. During the experimental
period animals were weighed and tumour sizes were measured
daily. Experimental studies commenced on day 13 following
injection of tumour cells, when tumours had an approximate
average size of 110 mm2. To study anti-cancer activity either
free doxorubicin (5 mgkg' animal body weight) or doxo-
rubicin- HPMA copolymer conjugate (5, 18, 27 or 36mgkg-',
relating to the doxorubicin content of the conjugate) was
administered i.p. in phosphate-buffered saline (0.1 ml) on
each of three consecutive days. Animals were sacrificed when
tumour size exceeded 450mm2, which occurred, for untreated
animals, approximately 20 days after tumour inoculation.
Measurement ofpharmacokinetics in vivo
Mice were inoculated with B16FIO cells and tumours allowed
to establish, as described above. Following administration via
the lateral tail vein of a single dose ofeither free doxorubicin
(5 mg kg-') or doxorubicin-HPMA copolymer conjugate
(with a doxorubicin content of 5 or 18mgkg-') in saline
(0.1 ml), animals were sacrificed (30min to 48 h) and
tumours immediately isolated, weighed and frozen. For
determination of doxorubicin levels, tumours were subse-
quently homogenised in known total volumes of phosphate-
buffered saline, and then daunomycin (200 ng) was added to
aliquot portions to act as an internal standard, prior to
extraction into three volumes of chloroform-propan-2-ol
(3:1, v/v). The organic phase was separated by centrifuga-
tion, decanted off and dried under nitrogen. The residue was
redissolved in methanol (100 l) for HPLC analysis using a
reversed phase 1i-Bondapak C,8 column, with mobile phase of
propan-2-ol (29%, v/v) in water, adjusted to pH 3.2 with
orthophosphoric acid. Anthracyclines were detected by
fluorescence (A 480 nm, A 560nm) and the size of the
daunomycin peak was used to quantify the amount of doxo-
rubicin present.
HPLC quantification of total doxorubicin, including doxo-
rubicin-HPMA copolymer conjugate, first required libera-
tion of the aglycone form of the drug from the copolymer by
acid-hydrolysis cleavage of the intramolecular glycosidic
bond. This method is known to give accurate determination
of polymer-bound doxorubicin (Seymour et al., 1990). Fol-
lowing careful neutralisation the sample was processed as
described above. Doxorubicin levels in tumours are expressed
as ng of doxorubicin per g of tumour tissue, and full
methodological details are given elsewhere (Seymour et al.,
1990). Values of areas under concentration-time curves638 L.W. SEYMOUR et al.
(AUC values) were calculated assuming linear changes
between observed values and expressed in units of (pg of
doxorubicin x hours per g of tissue).
Tumour levels of radioactivity (30min to 48 h) in homo-
genised samples were determined to quantify the presence of
HPMA copolymer backbone. Comparison of the quantities
of HPMA copolymer measured by radioactivity with the
quantities of doxorubicin determined by HPLC permits cal-
culation of rates of metabolism or disappearance of the drug
in vivo.
Fluorescence microscopy studies
Tumour-bearing mice were administered FITC-HPMA (7 mg
of conjugate. containing 4 nmol of FITC. dissolved in 0.1 ml
of saline per mouse) via the lateral tail vein. Tumours and
skeletal muscle samples were isolated after 10 min and 1. 24
and 72 h and fixed with acetone overnight, hand sectioned
and mounted on cavity slides with 10mg of p-phenylene
diamine to inhibit quenching of FITC fluorescence. Speci-
mens were examined using a Leitz Dialux microscope fitted
with epifluorescence optics. Dark-field fluorescent images
were recorded using Technical Pan film (Kodak) rated at 160
ASA. Fluorescent and control images were exposed for the
same time at the same magnification during the same obser-
vation penod.
Resiuts
Assessment ofanti-tumour efficacY
Treatment of mice bearing established s.c. tumours with free
doxorubicin (5 mg kg-' given daily for 3 days) achieved no
significant inhibition of tumour growth rate (Figure 2a) and
resulted in appreciable toxicity manifest as weight loss. In
four out of five mice in this treatment category animal weight
fell to 80% that of untreated matched control animals and
they were sacrificed. Treatment with the equivalent dose of
doxorubicin as HPMA copolymer conjugate (5 mg kg-' daily
for 3 days) also failed to inhibit tumour growth rate (Figure
2a). although this treatment resulted in no measurable weight
loss or other signs of toxicity. Therefore animals were also
treated with higher doses of doxorubicin-HPMA copolymer
conjugate (three daily doses of up to 36 mg kg-') and the
optimum dose level was found to be 27 mg kg-', which
achieved a median lifespan of 320% compared with untreat-
ed controls (Figure 2b). This was a significant improvement
in lifespan compared with controls or animals receiving treat-
ment with free doxorubicin (Mann-Whitney U-test. P<
0.005). Treatment at doses of 18 and 27 mg kg-' did not give
nse to any measurable toxicity as assessed by animal body
weight loss, and animals were eventually put down owing to
extensive tumour growth. Animals receiving the highest dose
of doxorubicin-HPMA copolymer conjugate (36 mg kg-')
developed substantial peritoneal and subcutaneous oedema
15 days following treatment. and were eventually sacrificed
for this reason rather than tumour growth.
Distribution ofdrugs andpolymer conjugates into s.c. tumours
Following i.v. administration of free doxorubicin (5 mg kg-',
single dose) to mice bearing established tumours, HPLC
analysis showed that tumour levels of free doxorubicin
reached a peak of 0.55 yg g- after 1 h and then declined
rapidly over the subsequent 11 h (Figure 3a and b). When an
equivalent dose of doxorubicin was administered as HPMA
copolymer conjugate, total doxorubicin levels measured in
the tumour rose to 7.5iLg g-' after 1 h. At first all of the
tumour-associated drug was present in HPMA copolymer-
conjugated form (Figure 3a), but subsequently free drug was
released from the carrier (Figure 3b). The maximum level of
free drug detected in the tumour tissue (0.45,.g g ') occurred
after 3 h, and this level was maintained approximately over
the subsequent 24 h. The tumour AUC for free doxorubicin
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Figure 2 Anti-tumour activity of free doxorubicin and doxo-
rubicin-HPMA copolymer conjugates when administered to C57
mice bearing established s.c. B16FIO melanoma. Tumour-bearing
mice were treated ip. on each of three successive days. and
tumour dimensions were measured daily, a. The growth of
tumours in control (saline-treated) animals (0). and those in
animals receiving a daily injection of doxorubicin (5 mg kg-') as
either free drug (0) or HPMA copolymer conjugate (0). b.
Tumour growth in animals receiving either saline (0) or doxo-
rubicin-HPMA copolymer conjugate (dailv injections containing
18 (0). 27 (M) or 36 (0) mg kg-' doxorubicin). n = 5. except
for animals treated with 36 mg kg-' drug conjugate (n = 3).
over the 48 h following administration of 5 mg kg-' free
doxorubicin was 8.7 .tg h g-'. The equivalent AUC values for
free and total (i.e. including both free and polymer-bound)
doxorubicin following administration of the same dose of
doxorubicin as HPMA copolymer conjugate were 15.22tig
h g' and 149.1 g h g-' respectively, representing increases
of 74.5% and 1,610% compared with the administration of
doxorubicin as free drug (Table I).
Treatment of tumour-bearing C57 mice with a single dose
of doxorubicin-HPMA copolymer conjugate, containing
18 gg-1 doxorubicin, produced total doxorubicin levels in
the tumour over 20 tLg g'l (Figure 3a) and free drug levels up
to 0.9 Lg g-' (Figure 3b). The AUCs for free and total
doxorubicin concentrations in the tumour over the first 48 h
were 40.1 iLg h g' and 671.7;Lg h g l respectively, represent-
ing increases of 360% and 7,603% compared with those
achieved following administration of 5 mg kg-' free doxo-
rubicin (Table I).
Figure 3c shows the levels of radioactivity measured in the
tumour following i.v. administration of doxorubicin-HPMA
copolymer conjugate (containing 5 mg kg-' doxorubicin. and
with a trace of radiolabelled conjugate). Data are expressedTUMOUR ACCUMULATION OF POLYMERIC PRODRUGS 639
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Figure 3 a and b. The tumour levels of doxorubicin determined
in s.c. B16F10 melanormas following i.v. administration of either
free doxorubicin (5 mg kg-'. 0) or doxorubicin-HPMA copoly-
mer conjugate (5 mg kg-'. 0: 18 mg kg-'. 0) to mice. a
represents the total amounts of doxorubicin (Jug g-' tissue)
measured in the tumour by HPLC. including polymer-bound
doxorubicin. while b represents the corresponding quantity of free
doxorubicin determined by HPLC in these samples. c. The quan-
tity of radioactivity associated with the tumours following i.v.
administration of '"-labelled doxorubicin-HPMA copolymer
conjugate at a total dose of 5 mg of doxorubicin per kg. Data are
expressed both as the percentage of administered radioactivity
recovered per g tumour and the equivalent theoretical quantity of
doxorubicin present. calculated assuming no degradation of the
conjugate. n = 5 or greater for each determination.
both in terms of the percentage administered radioactive dose
per g of tumour and also as the apparent quantity of doxo-
rubicin present based on levels of radioactivity and assuming
no cleavage or metabolism of the conjugate. At early times
there is close correlation between the levels of doxorubicin
predicted from measurement of radioactivity and those deter-
mined directly by HPLC (Figure 3a). However, at later times
the HPLC assay shows that there is actually less doxorubicin
Figue 4 Epifluorescence micrographs of s.c. BI6FO0 melanoma
tumours following i.v. injection of HPMA-FITC. a. Ten minutes
following administration of HPMA-FITC. fluorescence is highly
localised in the peripheral fibrous stroma (S) of the tumour, with
the highest intensity of fluorescence occurring near major blood
vessels within the region of attachment to the host tissue (A).
Fluorescence is also visible in the vascularised regions away from
the tumour attachment site (white arrows). No fluorescence is
visible in the interstitium (I). b. Seventy-two hours following i.v.
administration of HPMA-FITC, fluorescence is specifically con-
centrated in the peripheral fibrous stromal regions (S), and
especially at the point of tumour attachment (A) to the host
tissue. Little fluorescence is visible in the interstitium (I). Scale
bar= 1 mm.
TableI AUCvaluesfordoxorubicindetermined within solid s.c. B16FIOmelanomasfollowingi.. administration
of free doxorubicin or HPMA copolymer-doxorubicin conjugate
Tumour ALCo o free Tumour ALCo >,,,h total
Dose (mg doxorubicin- doxorubicin (ILg hg-' doxorubicin (ptg hg-'
Substrate administered equivalent kg-') tumour weight} tumour weight)
Doxorubicin 5 8.7 n a
HPMA copolymer- 5 15.2 149.1
doxorubicin conjugate
HPMA copolymer- 18 40.1 671.7
doxorubicin conjugate
n a. not appropriate.
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present in the tumour than would be predicted by measure-
ment of contained radioactivity. Since the radioactivity com-
ponent actually measures the presence of polymer backbone,
the disparity between the two determinations indicates that
the drug is being either released from the carrier and lost
from the tumour or metabolised to non-detected forms.
Fluorescence microscopic examination oftumour deposition of
macromolecules
In order to characterise better the mechanisms underlying the
anti-cancer activity of the polymer-drug conjugate, epifluo-
rescence microscopy was used to study the pattern of distri-
bution ofFHTC-HPMA copolymer conjugate in solid B16FI0
tumours. FITC-HPMA copolymer conjugate was initially
determined in blood vessels throughout the tumour vas-
culature, and rapid extravasation was evident within the
vascularsed stromal regions near the tumour periphery (data
no shown). After O min the connective tissue between the
tumour and subcutaneous muscle layer showed the greatest
level of fluorescence (Figure 4a). With increasing time the
amount of FITC-HPMA associated with the blood grad-
ually fell, and fluorescence became increasingly concentrated
within the connective tissue at the point of attachment to the
host muscle layer. After 72 h a thinner, well-defined, band of
fluorescence had developed, extending all the way around the
tumour (Figure 4b). Sections of tumours from matched con-
trol mice which received only saline or free FITC revealed no
sites of autofluorescence or non-specific fluorescence (not
shown).
Doxorubicin-HPMA copolymer conjugates have previously
shown improved activity in the treatment of a range of model
tumours (Duncan et al., 1988, 1989, 1992; O'Hare et al.,
1993). Here we have confirmed the powerful activity of this
drug conjugate in the treatment of establshed solid s.c.
B16FIO melanoma tumours. Optimal treatment using the
polymer-drug conjugate caused relatively little toxicity,
measured as animal weight loss, but mediated therapeutic
responses better than could be achieved using even aggressive
schedules of the free drug. The best dosage schedule
identified (3 x 27 mg of doxorubicin per kg as HPMA
copolymer conjugate) inhibited the rate of tumour growth for
at least 10 days following the end of treatment.
The doxorubicin-HPMA copolymer conjugate displayed a
passive tumour tropism previously recorded for a series of
HPMA copolymers of different molecular weights (Seymour
et al., 1994). This resulted in tumour loclisation of up to 5%
of the administered dose per g tumour, 10-15 times more
than that achieved using free doxorubicin administered at
equal doses (5 mg of doxorubicin per kg). Decreased toxicity
of the polymer-conjugated doxorubcin permitted use of
elevated doses, and single injections of doxorubicin-HPMA
copolymer conjugate bearing 18 mg of doxorubicin per kg
achieved tumour levels of drug 45-fold higher than those
resulting from the standard 5 mg kg-' dose of free doxo-
rubicin.
Following injection of doxorubicin-HPMA copolymer
conjugate (containing 5 mg of doxorubicin equivalent per
kg), HPLC analysis showed that levels of tumour-associated
doxorubicin (including copolymer-bound doxorubicin) show-
ed an initial rapid rise and reached a peak between 1 and 6 h
(Figure 3b). Studies using radiolabelled doxorubicin-HPMA
copolymer conjugate confirmed rapid tumour accumulation
immediately following administration, although tumour levels
of radioactivity continued to rise steadily over 12 h (Figure
3c). Comparison of these results implies that in the period
6-12 h following injection rates of doxorubicin disappear-
ance from the tumour are faster than rates of accumulation.
Disappearance of doxorubicin from the tumour may result
from its metabolism to undetected forms, or from its drain-
age out of the tumour, in either free or copolymer-conjugated
form. The rate of proteolytic release of free doxorubicin from
the copolymer conjugate is likely also to influence rates of
disappearance.
Cassidy et al. (1989) and Duncan et al. (1992) studied the
pharmacokinetics of daunomycin-HPMA copolymer con-
jugate within solid s.c. Walker sarcoma, finding initially very
high levels of the drug conjugate associated with the tumour.
Between 1 and 24 h the total levels of tumour-associated
daunomycin gradually fell, but the levels of free daunomycin
(i.e. liberated from the conjugate) showed a steady rise that
was still apparent after 24 h. Radiolabelled drug conjugates
were not employed in those studies, so no information is
available concerning tumour levels of the HPMA copolymer
itself. However, it is likely that the obvious differences from
the pharmacokinetic profiles reported here for B16FIO
melanoma may relate to physiological or metabolic differ-
ences between the two tumour types.
The doxorubicin-HPMA copolymer conjugate mediates
better anti-cancer activity than free doxorubicin against
B16FIO melanoma, particularly when applied at elevated
doses. The improved activity is more in proportion to the
increased tumour AUC values for free doxorubicin (elevated
1.7- to 4.6-fold) than for total doxorubicin (17.1- to 77.0-
fold), however, confirming that therapeutic activity of the
doxorubicin-HPMA copolymer conjugate is dependent on
proteolytic release of the free anthracycline. Hence, it is
possible that the therapeutic activity of high doses of the
doxorubicin-HPMA copolymer conjugate within this model
system may be limited by rates of proteolytic activation of
the polymeric prodrug within the solid tumour.
Epifluorescence microscopic examination of subcutaneous
B16FIO melanomas taken from C57 mice treated intraven-
ously with FITC-HPMA showed extravasation occurring in
tumour tissue within the first few minutes following injection.
The majority of extravasation and macromolecular deposi-
tion occurred within vascularised stromal areas of the
tumour, notably at the host-tumour interface. This suggests
that the doxorubicin-HPMA copolymer conjugate may also
become localised here, achieving highest concentrations in
sites of active tumour growth. The intratumoral distribution
of the macromolecule almost certainly influences its anti-
cancer effect, and may explain why no tumour shrinkage was
noted, despite the effective and prolonged inhibition of
tumour growth achieved.
The physiological cause of the passive tumour tropism of
the drug conjugate is thought to involve the modified path-
ways of fluid extravasation and tissue drainage in tumours.
Tumour tissue differs from normal tissue in having ineffective
or absent pathways of lymphatic drainage, resulting in poor
fluid convection and elevated interstitial hydrostatic pressures
(Jain, 1990). This leads to poor oxygenation of the tumour
mass, and induces the release of angiogenic and capillary-
permeabilising factors such as vascular endothelial growth
factor in order to improve the supply of oxygen and nut-
rients (Ferrara et al., 1992). The increased permeability of
tumour vasculature also facilitates extravasation of macro-
moleules, including copolymer-drug conjugates, from the
bloodstream into the tumour interstitium. However many of
these macromolecules are unable to return to the circulation
via the lymphatics, instead frequently remaining and
accumulating within the tumour. This phenomenon of pas-
sive tumour tropism of soluble macromolecules and drug
conjugates has been described before and termed the enhanc-
ed permeability and retention (EPR) effect (Matsumura &
Maeda, 1986; Seymour, 1992).
The mechanism of anti-cancer activity of doxorubicin-
HPMA copolymer conjugate may depend on its modified
pharmacokinetics, notably its relative accumulation within
tumours. Despite encouraging preclinical evidence, however,
it remains unclear whether this phenomenon is typical of
human clinical disease, including slowly growing tumours.
Tumour-imaging using gallium-67 has been suggested to
result from the accumulation of transferrin-bound isotope
within tumour tissue (Maeda, 1991), and may also depend on
the EPR effect described above. The usefulness of gallium-67TUMOUR ACCUMULATION OF POLYMERIC PRODRUGS 641
in imaging lymphomas (Hodgkin's and non-Hodgkin's; John-
ston et al., 1974), hepatomas (Suzuki et al., 1971) and certain
other solid carcinomas (Nelson et al.. 1972) suggests that the
phenomenon may be of clinical relevance, with polymer-
bound drugs consequently finding a number of therapeutic
applications.
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